0%
Products > TruDiagnosis® > TruArray MDR-TB Assay
Quick and reliable identification of drug resistant strains of Mycobacterium tuberculosis (MTB) from bacterial culture or human sputum is challenging. Existing molecular diagnostic (MDx) systems are typically too large for crowded laboratories, require a large investment in capital equipment, are too complex to use without extensive training or do not sample across a broad enough range of resistant strains.
The highly accurate and reliable TruArray MDR-TB assay is a portable, bench-top assay that detects mycobacterial susceptibility to rifampin and isoniazid, using a single, integrated-workflow approach. And, unlike other methods that may take days, weeks or even months to test for drug resistance, TruArray MDR-TB delivers results in a few hours.
Image of a TruArray MDR-TB assay result demonstrating how the system
differentiates between rifampin-susceptible and rifampin-resistant MTB.
Linger Y, Kukhtin A, Golova J, Perov A, Qu P, Knickerbocker C, Cooney CG, Chandler DP. 2014. Demonstrating a multi-drug resistant Mycobacterium tuberculosis amplification microarray. J. Vis. Exp. 25;(86). doi: 10.3791/51256.
Linger Y, Kukhtin A, Golova J, Perov A, Lambarqui A, Bryant L, Rudy GB, Dionne K, Fisher SL, Parrish N, Chandler DP. 2014. Simplified microarray system for simultaneously detecting rifampin, isoniazid, ethambutol, and streptomycin resistance markers in Mycobacterium tuberculosis. J. Clin. Microbiol. 52(6):2100-7.
* All of Akonni Biosystems tests are currently for Research Use Only, and are not for use in diagnostic procedures. Akonni is interacting with the Food & Drug Administration (FDA) in order to develop and prepare pre-market notifications seeking clearance to market these products as diagnostic assays in the U.S.
Based on its recent analysis of the microarrays in molecular diagnostics (MDx) market, Frost & Sullivan recognizes Akonni Biosystems with the 2017 North American New Product Innovation Award.
Akonni’s integrated MDx system, TruDiagnosis®, is revolutionizing the point-of-care molecular testing market by enabling target detection from a variety of sample types. TruDiagnosis® is powered by TruArray®, a patented 3D gel-drop microarray technology for sample screening that instantly indicates the presence of disease markers in real time.
Download:
